1. prisoner 2. pregnancy 3. breast feeding 4. current infectious or noninfectious diarrheal illness 5. unable to randomize within 21 days after onset of acute respiratory infection symptoms 6. unable to randomize after hospital arrival 7. colonic obstruction 8. unresolved hypovolemia 9. crcl \<30ml/min 10. hypermagnesemia 11. diagnosis of long qt syndrome 12. known allergy to magnesium citrate or probiotic 13. unresolved electrolyte imbalance such as hypokalemia or hypocalcemia. the patient can be enrolled if electrolytes are corrected and sustained. 14. receipt of \>1 dose of magnesium citrate or any other colonic cleanser in the 7 days prior to enrollment 15. inability to receive enteral medications 16. refusal or inability to be contacted on day 15 for clinical outcome assessment if discharged prior to day 15 17. concurrent medical illness that interferes with clinical assessment previous enrollment in this trial 18. the treating clinical team does not believe equipoise exists regarding the use of magnesium citrate plus a probiotic for the treatment of this patient. 19. participating in any other covid-19 therapeutic trial 20. allergic to soy. 21. lactose intolerant.

1. prisoner 2. pregnancy 3. breast feeding 4. current infectious or noninfectious diarrheal illness 5. unable to randomize within 21 days after onset of acute respiratory infection symptoms 6. unable to randomize after hospital arrival 7. colonic obstruction 8. unresolved hypovolemia 9. crcl \<30ml/min 10. hypermagnesemia 11. diagnosis of long qt syndrome 12. known allergy to magnesium citrate or probiotic 13. unresolved electrolyte imbalance such as hypokalemia or hypocalcemia. the patient can be enrolled if electrolytes are corrected and sustained. 14. receipt of \>1 dose of magnesium citrate or any other colonic cleanser in the 7 days prior to enrollment 15. inability to receive enteral medications 16. refusal or inability to be contacted on day 15 for clinical outcome assessment if discharged prior to day 15 17. concurrent medical illness that interferes with clinical assessment previous enrollment in this trial 18. the treating clinical team does not believe equipoise exists regarding the use of magnesium citrate plus a probiotic for the treatment of this patient. 19. participating in any other covid-19 therapeutic trial 20. allergic to soy. 21. lactose intolerant.

prisoner pregnancy breast feeding current infectious or noninfectious diarrheal illness unable to randomize within 21 days after onset of acute respiratory infection symptoms unable to randomize after hospital arrival colonic obstruction unresolved hypovolemia crcl <30ml/min hypermagnesemia diagnosis of long qt syndrome known allergy to magnesium citrate or probiotic unresolved electrolyte imbalance such as hypokalemia or hypocalcemia. the patient can be enrolled if electrolytes are corrected and sustained. receipt of >1 dose of magnesium citrate or any other colonic cleanser in the 7 days prior to enrollment inability to receive enteral medications refusal or inability to be contacted on day 15 for clinical outcome assessment if discharged prior to day 15 concurrent medical illness that interferes with clinical assessment previous enrollment in this trial the treating clinical team does not believe equipoise exists regarding the use of magnesium citrate plus a probiotic for the treatment of this patient. participating in any other covid-19 therapeutic trial allergic to soy. lactose intolerant.

prisoner pregnancy breast feeding current infectious or noninfectious diarrheal illness unable to randomize within 21 days after onset of acute respiratory infection symptoms unable to randomize after hospital arrival colonic obstruction unresolved hypovolemia crcl <30ml/min hypermagnesemia diagnosis of long qt syndrome known allergy to magnesium citrate or probiotic unresolved electrolyte imbalance such as hypokalemia or hypocalcemia. the patient can be enrolled if electrolytes are corrected and sustained. receipt of >1 dose of magnesium citrate or any other colonic cleanser in the 7 days prior to enrollment inability to receive enteral medications refusal or inability to be contacted on day 15 for clinical outcome assessment if discharged prior to day 15 concurrent medical illness that interferes with clinical assessment previous enrollment in this trial the treating clinical team does not believe equipoise exists regarding the use of magnesium citrate plus a probiotic for the treatment of this patient. participating in any other covid-19 therapeutic trial allergic to soy. lactose intolerant.

1. prisoner 2. pregnancy 3. breast feeding 4. current infectious or noninfectious diarrheal illness 5. unable to randomize within 21 days after onset of acute respiratory infection symptoms 6. unable to randomize after hospital arrival 7. colonic obstruction 8. unresolved hypovolemia 9. crcl <30ml/min 10. hypermagnesemia 11. diagnosis of long qt syndrome 12. known allergy to magnesium citrate or probiotic 13. unresolved electrolyte imbalance such as hypokalemia or hypocalcemia. the patient can be enrolled if electrolytes are corrected and sustained. 14. receipt of >1 dose of magnesium citrate or any other colonic cleanser in the 7 days prior to enrollment 15. inability to receive enteral medications 16. refusal or inability to be contacted on day 15 for clinical outcome assessment if discharged prior to day 15 17. concurrent medical illness that interferes with clinical assessment previous enrollment in this trial 18. the treating clinical team does not believe equipoise exists regarding the use of magnesium citrate plus a probiotic for the treatment of this patient. 19. participating in any other covid-19 therapeutic trial 20. allergic to soy. 21. lactose intolerant.

1. prisoner 2. pregnancy 3. breast feeding 4. current infectious or noninfectious diarrheal illness 5. unable to randomize within 21 days after onset of acute respiratory infection symptoms 6. unable to randomize after hospital arrival 7. colonic obstruction 8. unresolved hypovolemia 9. crcl <30ml/min 10. hypermagnesemia 11. diagnosis of long qt syndrome 12. known allergy to magnesium citrate or probiotic 13. unresolved electrolyte imbalance such as hypokalemia or hypocalcemia. the patient can be enrolled if electrolytes are corrected and sustained. 14. receipt of >1 dose of magnesium citrate or any other colonic cleanser in the 7 days prior to enrollment 15. inability to receive enteral medications 16. refusal or inability to be contacted on day 15 for clinical outcome assessment if discharged prior to day 15 17. concurrent medical illness that interferes with clinical assessment previous enrollment in this trial 18. the treating clinical team does not believe equipoise exists regarding the use of magnesium citrate plus a probiotic for the treatment of this patient. 19. participating in any other covid-19 therapeutic trial 20. allergic to soy. 21. lactose intolerant.